Agenda BJCN-MORE 2023
Management of Esophageal and Gastroesophageal Junction Carcinoma
Tele-oncology and BJCN Cluster Interactions
9 November
10 November
11 November
12 November
9 November
Official opening
Annual Award BJCN-MORÉ – for contribution to Bulgarian clinical oncology
Symposium BMS
Gastro-Esophageal Cancer and Immuno-Oncology Today: Best Practice and
Clinical Challenges
Chairman:: Assoc. Prof. Dr. A. Konsoulova
17:20 – 17:40 Biomarker overview in upper gastrointestinal (uGI) cancers
Prof. Dr. S. Popovska
17:40 – 18:00 Current treatment options in uGI cancers
Dr. M. Koleva
18:00 – 18:10 Case presentations
Dr. K. Koynov
18:10 – 18:20 Discussion
Chairman:: Assoc. Prof. Dr. A. Konsoulova
17:20 – 17:40 Biomarker overview in upper gastrointestinal (uGI) cancers
Prof. Dr. S. Popovska
17:40 – 18:00 Current treatment options in uGI cancers
Dr. M. Koleva
18:00 – 18:10 Case presentations
Dr. K. Koynov
18:10 – 18:20 Discussion
Symposium Varia
Chairman:: Prof. Dr. J. Grudeva
18:25 – 18:45 Place of Lumikras in patients with non-small cell lung cancer (NSCLC))
Dr. V. Kanarev, Amgen
18:45 – 19:05 First-line treatment with avelumab in advanced or metastatic urothelial carcinoma – already two years in Bulgaria
Assoc. Prof. Dr. A. Konsoulova, Merck
19:05 – 19:15 First-line therapy with Kisqali prolongs survival in metastatic breast carcinoma
Assoc. Prof. Dr. A. Konsoulova, Novartis
19:15 – 19:25 Do patients with metastatic breast carcinoma and aggressive visceral disease need first-line chemotherapy
Dr. K. Koynov, Novartis
19:25 – 19:45 Current therapeutic options for the treatment of metastatic hormone- sensitive prostate cancer – role of apalutamide in the treatment algorithm
Dr. R. Mangaldjiev, Johnson & Johnson
19:45 – 20:05 Verzenios: a new approach in the treatment of HR+, HER2- early CG – in patients with axillary lymph node involvement, at high risk of relapse
Assoc. Prof. Dr. A. Konsoulova, Eli Lilly
18:25 – 18:45 Place of Lumikras in patients with non-small cell lung cancer (NSCLC))
Dr. V. Kanarev, Amgen
18:45 – 19:05 First-line treatment with avelumab in advanced or metastatic urothelial carcinoma – already two years in Bulgaria
Assoc. Prof. Dr. A. Konsoulova, Merck
19:05 – 19:15 First-line therapy with Kisqali prolongs survival in metastatic breast carcinoma
Assoc. Prof. Dr. A. Konsoulova, Novartis
19:15 – 19:25 Do patients with metastatic breast carcinoma and aggressive visceral disease need first-line chemotherapy
Dr. K. Koynov, Novartis
19:25 – 19:45 Current therapeutic options for the treatment of metastatic hormone- sensitive prostate cancer – role of apalutamide in the treatment algorithm
Dr. R. Mangaldjiev, Johnson & Johnson
19:45 – 20:05 Verzenios: a new approach in the treatment of HR+, HER2- early CG – in patients with axillary lymph node involvement, at high risk of relapse
Assoc. Prof. Dr. A. Konsoulova, Eli Lilly
Welcome dinner
10 November
FIRST PLENARY SESSION
Pretherapeutic and diagnostic issues in esophageal and gastroesophageal
junction (GJC) carcinoma
Chairman: Prof. Dr. D. Toncheva
08:00 – 08:15 Update on the GRADE approach
Assoc. Prof. Dr. D. Kalev
08:20 – 08:40 Genetic architecture of esophageal carcinoma
Prof. Dr. D. Toncheva
08:45 – 09:05 Liquid biopsy as a method of diagnosis, prognosis and prediction
Assoc. Prof. M. Georgieva
09:10 – 09:30 Value of screening endoscopy and target population in esophageal carcinoma and GJC: how early detection and prevention strategies can be improved
Dr. Z. Gorcheva, Assoc. Prof. Dr. P. Karagyozov
09:35 – 09:55 Cellular and molecular drivers in Barrett’s esophagus and adenocarcinoma
Assoc. Prof. Dr. S. Bachurska
10:00 – 10:20 Clinical significance of the microbiome in upper gastrointestinal carcinomas
Dr. M. Koleva
10:25 – 10:45 Benefits, pitfalls, and artificial intelligence (AI) in hybrid imaging of esophageal carcinoma
Prof. Dr. E. Piperkova, Dr. L. Chavdarova, Prof. Dr. I. Kostadinova
Chairman: Prof. Dr. D. Toncheva
08:00 – 08:15 Update on the GRADE approach
Assoc. Prof. Dr. D. Kalev
08:20 – 08:40 Genetic architecture of esophageal carcinoma
Prof. Dr. D. Toncheva
08:45 – 09:05 Liquid biopsy as a method of diagnosis, prognosis and prediction
Assoc. Prof. M. Georgieva
09:10 – 09:30 Value of screening endoscopy and target population in esophageal carcinoma and GJC: how early detection and prevention strategies can be improved
Dr. Z. Gorcheva, Assoc. Prof. Dr. P. Karagyozov
09:35 – 09:55 Cellular and molecular drivers in Barrett’s esophagus and adenocarcinoma
Assoc. Prof. Dr. S. Bachurska
10:00 – 10:20 Clinical significance of the microbiome in upper gastrointestinal carcinomas
Dr. M. Koleva
10:25 – 10:45 Benefits, pitfalls, and artificial intelligence (AI) in hybrid imaging of esophageal carcinoma
Prof. Dr. E. Piperkova, Dr. L. Chavdarova, Prof. Dr. I. Kostadinova
Coffee break
SECOND PLENARY SESSION
Surgical strategies in esophageal and gastroesophageal junction carcinoma
Chairman: Prof. Dr. N. Vladov
11:10 – 11:30 Endoscopic control of early esophageal carcinoma and GJC – pitfalls and outcomes
Assoc. Prof. Dr. A. Katzarov
11:35 – 11:55 Traditions and modifications in the Ivor Lewis esophagectomy technique
Assoc. Prof. Dr. N. Belev
12:00 – 12:40 Ivor Lewis steps in minimally invasive and robotic esophagectomy and protocols for three-field McKeown esophagectomy
Assoc. Prof. Dr. Tz. Minchev
12:45 – 13:05 Transhiatal esophagectomy
Prof. Dr. D. Kostov, Dr. J. Kalcheva
13:10 – 13:30 Liver metastases from esophageal carcinoma – is there a role for surgical resection
Dr. R. Kostadinov, Dr. Tz.Trichkov, Assoc. Prof. Dr. V. Mihailov, Prof. Dr. N. Vladov
Chairman: Prof. Dr. N. Vladov
11:10 – 11:30 Endoscopic control of early esophageal carcinoma and GJC – pitfalls and outcomes
Assoc. Prof. Dr. A. Katzarov
11:35 – 11:55 Traditions and modifications in the Ivor Lewis esophagectomy technique
Assoc. Prof. Dr. N. Belev
12:00 – 12:40 Ivor Lewis steps in minimally invasive and robotic esophagectomy and protocols for three-field McKeown esophagectomy
Assoc. Prof. Dr. Tz. Minchev
12:45 – 13:05 Transhiatal esophagectomy
Prof. Dr. D. Kostov, Dr. J. Kalcheva
13:10 – 13:30 Liver metastases from esophageal carcinoma – is there a role for surgical resection
Dr. R. Kostadinov, Dr. Tz.Trichkov, Assoc. Prof. Dr. V. Mihailov, Prof. Dr. N. Vladov
Lunch
THIRD PLENARY SESSION
Problems of perioperative approaches in esophageal and gastroesophageal
junction carcinoma
Chairman: Assoc. Prof. Dr. V. Ivanova
14:30 – 14:50 Classification of pathologic response from neoadjuvant therapy in esophageal carcinoma and GJC
Assoc. Prof. Dr. I. Ivanov
14:55 – 15:15 Imaging biomarkers in the treatment of esophageal carcinoma
Assoc. Prof. Dr. V. Stoynova, Dr. N. Mladenova, Prof. Dr. G. Kirova
15:20 – 15:40 Prediction of pCR and detection of residual disease in neoadjuvant chemoradiotherapy for esophageal carcinoma
Assoc. Prof. Dr. V. Ivanova
15:45 – 16:05 The unusual patient with ypT0N+ esophageal carcinoma – what’s next
Assoc. Prof. Dr. N. Chilingirova
Chairman: Assoc. Prof. Dr. V. Ivanova
14:30 – 14:50 Classification of pathologic response from neoadjuvant therapy in esophageal carcinoma and GJC
Assoc. Prof. Dr. I. Ivanov
14:55 – 15:15 Imaging biomarkers in the treatment of esophageal carcinoma
Assoc. Prof. Dr. V. Stoynova, Dr. N. Mladenova, Prof. Dr. G. Kirova
15:20 – 15:40 Prediction of pCR and detection of residual disease in neoadjuvant chemoradiotherapy for esophageal carcinoma
Assoc. Prof. Dr. V. Ivanova
15:45 – 16:05 The unusual patient with ypT0N+ esophageal carcinoma – what’s next
Assoc. Prof. Dr. N. Chilingirova
Coffee break
Symposium MSD
Implementation of pembrolizumab treatment strategies in clinical practice
Chairman: Assoc. Prof. Dr. D. Kalev
16:30 – 16:40 Opening remarks
16:40 – 17:00 First-line pembrolizumab combination therapy in patients with metastatic non-small cell lung cancer – one patient, two diagnoses and many questions
Dr. K. Koynov
17:00 – 17:20 Triple negative breast cancer – from clinical studies to real practice
Assoc. Prof. Dr. A. Konsoulova
17:20 – 17:30 Discussion
Chairman: Assoc. Prof. Dr. D. Kalev
16:30 – 16:40 Opening remarks
16:40 – 17:00 First-line pembrolizumab combination therapy in patients with metastatic non-small cell lung cancer – one patient, two diagnoses and many questions
Dr. K. Koynov
17:00 – 17:20 Triple negative breast cancer – from clinical studies to real practice
Assoc. Prof. Dr. A. Konsoulova
17:20 – 17:30 Discussion
DISCUSSION SESSION
Expert discussion Pros/Cons
Chairman: Prof. Dr. T. Hadjieva
17:35 – 17:55 Management of T1b esophageal carcinoma: endoscopic resection versus esophagectomy
Assoc. Prof. Dr. P. Karagyozov vs Assoc. Prof. Dr. N. Belev
17:55 – 18:15 Neoadjuvant therapy in esophageal adenocarcinoma and GJC: chemotherapy versus radiochemotherapy
Dr. M. Koleva vs Prof. Dr. T. Hadjieva
18:15 – 18:35 Treatment of locally advanced esophageal squamous cell carcinoma: definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery
Dr. K. Yordanov vs Dr. K. Nedev
Chairman: Prof. Dr. T. Hadjieva
17:35 – 17:55 Management of T1b esophageal carcinoma: endoscopic resection versus esophagectomy
Assoc. Prof. Dr. P. Karagyozov vs Assoc. Prof. Dr. N. Belev
17:55 – 18:15 Neoadjuvant therapy in esophageal adenocarcinoma and GJC: chemotherapy versus radiochemotherapy
Dr. M. Koleva vs Prof. Dr. T. Hadjieva
18:15 – 18:35 Treatment of locally advanced esophageal squamous cell carcinoma: definitive radiochemotherapy versus neoadjuvant radiochemotherapy followed by surgery
Dr. K. Yordanov vs Dr. K. Nedev
Symposium AstraZeneca
Innovation in the near future
Chairman: Assoc. Prof. Dr. A. Konsoulova
18:45 – 19:05 What’s new on the horizon in the treatment of HER2-negative early breast cancer and metastatic castration-resistant prostate cancer (mCRPC)
Dr. R. Mangaldjiev
19:05 – 19:25 Unfolding the spectrum of options in the treatment of advanced HER2- positive gastric cancer
Dr. M. Koleva
19:25 – 19:45 Breakthrough of immunotherapy in the treatment of unresectable or metastatic bile ducts carcinoma (BDC)
Dr. M. Koleva
Chairman: Assoc. Prof. Dr. A. Konsoulova
18:45 – 19:05 What’s new on the horizon in the treatment of HER2-negative early breast cancer and metastatic castration-resistant prostate cancer (mCRPC)
Dr. R. Mangaldjiev
19:05 – 19:25 Unfolding the spectrum of options in the treatment of advanced HER2- positive gastric cancer
Dr. M. Koleva
19:25 – 19:45 Breakthrough of immunotherapy in the treatment of unresectable or metastatic bile ducts carcinoma (BDC)
Dr. M. Koleva
Dinner
11 November
FOURTH PLENARY SESSION
Systemic, radiotherapy and palliative strategies in esophageal and
gastroesophageal junction carcinoma
Chairman: Prof. Dr. M. Genova
08:00 – 08:20 Sensitivity of hematologic markers in patients receiving therapy for esophageal carcinoma
Prof. Dr. M. Genova, Prof. Dr. G. Balatzenco
08:25 – 08:45 Targets in systemic therapy in esophageal carcinoma and GJC
Dr. R. Mangaldjiev
08:50 – 09:10 Integration of immunotherapy across all lines of treatment in esophageal carcinoma and GJC – prediction with PD-L1, MSI, and TMB
Assoc. Prof. Dr. A. Konsoulova
09:15 – 09:35 Chemoradiation in oligometastatic disease from esophageal carcinoma
Prof. Dr. T. Hadjieva, Dr. M. Koleva
09:40 – 10:00 Effect of early nutritional support on clinical outcomes in esophageal carcinoma
Assoc. Prof. Dr. N. Yordanov
Chairman: Prof. Dr. M. Genova
08:00 – 08:20 Sensitivity of hematologic markers in patients receiving therapy for esophageal carcinoma
Prof. Dr. M. Genova, Prof. Dr. G. Balatzenco
08:25 – 08:45 Targets in systemic therapy in esophageal carcinoma and GJC
Dr. R. Mangaldjiev
08:50 – 09:10 Integration of immunotherapy across all lines of treatment in esophageal carcinoma and GJC – prediction with PD-L1, MSI, and TMB
Assoc. Prof. Dr. A. Konsoulova
09:15 – 09:35 Chemoradiation in oligometastatic disease from esophageal carcinoma
Prof. Dr. T. Hadjieva, Dr. M. Koleva
09:40 – 10:00 Effect of early nutritional support on clinical outcomes in esophageal carcinoma
Assoc. Prof. Dr. N. Yordanov
Comprehensive genomic profiling
Clinical value of comprehensive genomic profiling with Foundation Medicine in lung
cancer patients
Dr. M. Koleva
Dr. M. Koleva
Coffee break
Symposium Pierre Fabre
Chairman: Assoc. Prof. Dr. D. Kalev
10:55 – 11:00 Opening remarks
11:00 – 11:25 Clinical challenges in metastatic colorectal carcinoma (mCRC) with BRAF V600E mutation, targeted therapy with the encorafenib & cetuximab combination
Dr. P. Balikova
11:25 – 11:50 Encorafenib & binimetinib treatment of unresectable or metastatic melanoma with BRAF V600 mutation
Dr. G. Shalamanova
11:50 – 11:55 Discussion
10:55 – 11:00 Opening remarks
11:00 – 11:25 Clinical challenges in metastatic colorectal carcinoma (mCRC) with BRAF V600E mutation, targeted therapy with the encorafenib & cetuximab combination
Dr. P. Balikova
11:25 – 11:50 Encorafenib & binimetinib treatment of unresectable or metastatic melanoma with BRAF V600 mutation
Dr. G. Shalamanova
11:50 – 11:55 Discussion
Symposium Pfizer
Science meets practice for a better tomorrow for patients with HR+/HER2-
metastatic breast cancer (mBC)
Chairman: Assoc. Prof. Dr. A. Konsoulova
12:00 – 12:20 After eight years of experience and evidence – increasingly confident in the treatment of HR+/HER2- mBC in a wide range of patients
Dr. K. Koynov
12:20 – 12:40 The real practice in the treatment of HR+/HER2- mBC through the perspective of local clinical experience
Dr. K. Nikolov
12:40 – 13:00 Discussion
Chairman: Assoc. Prof. Dr. A. Konsoulova
12:00 – 12:20 After eight years of experience and evidence – increasingly confident in the treatment of HR+/HER2- mBC in a wide range of patients
Dr. K. Koynov
12:20 – 12:40 The real practice in the treatment of HR+/HER2- mBC through the perspective of local clinical experience
Dr. K. Nikolov
12:40 – 13:00 Discussion
Lunch
Symposium Roche
Chairman: Dr. R. Mangaldjiev
14:00 – 14:05 Opening remarks
14:05 – 14:25 Phesgo benefits for patients and healthcare professionals beyond efficacy – an example from real clinical practice
Assoc. Prof. Dr. A. Konsoulova
14:25 – 14:40 Change in the standard of care in non-small cell lung carcinoma (NSCLC) early stage
Dr. V. Minchev
14:00 – 14:05 Opening remarks
14:05 – 14:25 Phesgo benefits for patients and healthcare professionals beyond efficacy – an example from real clinical practice
Assoc. Prof. Dr. A. Konsoulova
14:25 – 14:40 Change in the standard of care in non-small cell lung carcinoma (NSCLC) early stage
Dr. V. Minchev
FIRST BJCN JOINT SESSION
Integrative Oncology
Chairman: Dr. P. Zagorchev
14:45 – 15:05 Possibilities of homeopathy in the integrative approach in oncological patients
Dr. J-L Bagot
15:05 – 15:15 My experience in complementary treatment in cancer patients
Dr. P. Zagorchev
15:15 – 15:25 Possibilities of homeopathy to support the cancer patient in the general practitioner’s office
Dr. I. Enev
15:25 – 15:40 Discussion
Chairman: Dr. P. Zagorchev
14:45 – 15:05 Possibilities of homeopathy in the integrative approach in oncological patients
Dr. J-L Bagot
15:05 – 15:15 My experience in complementary treatment in cancer patients
Dr. P. Zagorchev
15:15 – 15:25 Possibilities of homeopathy to support the cancer patient in the general practitioner’s office
Dr. I. Enev
15:25 – 15:40 Discussion
SECOND BJCN JOINT SESSION
Cluster interaction potentials in BJCN: multipliers, mutual benefits and
ecosystem effects
Chairman: Assoc. Prof. Dr. D. Kalev
15:45 – 15:50 Welcome and introductions
15:50 – 16:05 Projects with the participation of BJCN – presentation with perspectives
I. Petrov
16:05 – 16:20 BJCN programs for continuing medical education in oncology and oncohematology
Prof. Dr. M. Genova
16:20 – 16:25 Discussion
Chairman: Assoc. Prof. Dr. D. Kalev
15:45 – 15:50 Welcome and introductions
15:50 – 16:05 Projects with the participation of BJCN – presentation with perspectives
I. Petrov
16:05 – 16:20 BJCN programs for continuing medical education in oncology and oncohematology
Prof. Dr. M. Genova
16:20 – 16:25 Discussion
Coffee break
THIRD BJCN JOINT SESSION
Tele-oncology in the social triangle – research, technologies, and policies
Part I: Keynote panel
Chairmans: I. Cattaneo
16:50 – 17:05 Uniting against Cancer: ECHoS Project
Y. Fonseca
Agency for Clinical Research and Biomedical Innovation (AICIB), Portugal
17:05 – 17:20 Innovation in Cancer Primary Prevention – The 4P-CAN Project
Dr. M. Geantă, B. Cucoș
Centre for Innovation in Medicine (InoMed), Romania
17:20 – 17:35 Comprehensive Cancer Infrastructures
E. Griesshammer, German Cancer Society
17:35 – 17:50 eCAN – A Joint Action of 16 EU Member States for strengthening telemedicine in cancer care
T. Schmitt, K. Habimana
Strengthening eHealth for Cancer Prevention and Care (eCAN Joint Action) [TBC]
17:50 – 18:05 Digital solutions for monitoring patient symptoms and adverse drug events
Prof. Dr. G. Velikova
University of Leeds, UK
18:05 – 18:15 The point of view of a Cancer center General Manager
Dr. V. Daskalov, National Oncology Hospital – Bulgaria
18:15 – 18:20 Concluding remarks
Part II: Discussion panel
Chairmans: Dr. A. Simidchiev
18:25 – 19:25 Action-oriented discussion
With representatives from: Ministry of Health, Ministry of Innovation and Growth, Medical University of Pleven, National Oncology Hospital – Bulgaria, Municipality of Varna, Bulgarian Cluster for Digital Solutions and Innovations in Health Care, National Patient Organization, Junior Achievement Bulgaria, Law Office Murgova and Partners, BJCN
19:40 – 19:45 Memorandum and concluding remarks
Part I: Keynote panel
Chairmans: I. Cattaneo
European Federation of Pharmaceutical Industries and Associations
(EFPIA)
I. Petrov, BJCN
16:50 – 17:05 Uniting against Cancer: ECHoS Project
Y. Fonseca
Agency for Clinical Research and Biomedical Innovation (AICIB), Portugal
17:05 – 17:20 Innovation in Cancer Primary Prevention – The 4P-CAN Project
Dr. M. Geantă, B. Cucoș
Centre for Innovation in Medicine (InoMed), Romania
17:20 – 17:35 Comprehensive Cancer Infrastructures
E. Griesshammer, German Cancer Society
17:35 – 17:50 eCAN – A Joint Action of 16 EU Member States for strengthening telemedicine in cancer care
T. Schmitt, K. Habimana
Strengthening eHealth for Cancer Prevention and Care (eCAN Joint Action) [TBC]
17:50 – 18:05 Digital solutions for monitoring patient symptoms and adverse drug events
Prof. Dr. G. Velikova
University of Leeds, UK
18:05 – 18:15 The point of view of a Cancer center General Manager
Dr. V. Daskalov, National Oncology Hospital – Bulgaria
18:15 – 18:20 Concluding remarks
Part II: Discussion panel
Chairmans: Dr. A. Simidchiev
Assoc. Prof. Dr. D. Kalev
18:20 – 18:25 Welcome and introductions18:25 – 19:25 Action-oriented discussion
With representatives from: Ministry of Health, Ministry of Innovation and Growth, Medical University of Pleven, National Oncology Hospital – Bulgaria, Municipality of Varna, Bulgarian Cluster for Digital Solutions and Innovations in Health Care, National Patient Organization, Junior Achievement Bulgaria, Law Office Murgova and Partners, BJCN
19:40 – 19:45 Memorandum and concluding remarks
Dinner
12 November
FOURTH BJCN JOINT SESSION
Health technologies panorama in Bulgarian oncology
Chairman: I. Lekushev
08:30 – 08:40 Referendo – digital platform for patient referendum
R. Dimitrov, B-eye
08:40 – 08:50 A revolution in cervical cancer screening
P. Prandzhev, GYNie.ai
08:50 – 09:00 Digital technologies to empower care and cross-border research in oncology
E. Syundyukov, Medical technology startup company Longenesis, Riga, Latvia
09:00 – 09:10 A digital platform for real-world data analysis
D. Taneva, MYSynergy
09:10 – 09:20 МОРЕ e-Guidelines – from the GRADE approach to AI
I. Lekushev, I. Dragoeva, BGO Software
09:20 – 09:30 Bringing sponsors, investigators, and research sites through the digital application ‘FIND MORE’
М. Jekov, Sqilline
09:30 – 09:40 Discover PrOPA – one story by Shemha Health
I. Petrov, Shemha Health
09:40 – 10:00 Discussion
Chairman: I. Lekushev
08:30 – 08:40 Referendo – digital platform for patient referendum
R. Dimitrov, B-eye
08:40 – 08:50 A revolution in cervical cancer screening
P. Prandzhev, GYNie.ai
08:50 – 09:00 Digital technologies to empower care and cross-border research in oncology
E. Syundyukov, Medical technology startup company Longenesis, Riga, Latvia
09:00 – 09:10 A digital platform for real-world data analysis
D. Taneva, MYSynergy
09:10 – 09:20 МОРЕ e-Guidelines – from the GRADE approach to AI
I. Lekushev, I. Dragoeva, BGO Software
09:20 – 09:30 Bringing sponsors, investigators, and research sites through the digital application ‘FIND MORE’
М. Jekov, Sqilline
09:30 – 09:40 Discover PrOPA – one story by Shemha Health
I. Petrov, Shemha Health
09:40 – 10:00 Discussion
Coffee break
JOINT BJCN ROUND TABLE
BJCN Cluster interaction – Capacity building
Chairman: Assoc. Prof. Dr. D. Kalev
With the participation of representatives from all BJCN members organizations
Chairman: Assoc. Prof. Dr. D. Kalev
With the participation of representatives from all BJCN members organizations
